Sir, We have read with interest the article recently published in JAC, 1 which analysed a large series of uncommon yeast fungaemias in France. We are also concerned about the increasing incidence of these episodes, mainly reported in immunosuppressed patients, 2, 3 which could potentially change future strategies for antifungal management. Therefore, we would like to add our experience from a large tertiary hospital in Spain.
We analysed all episodes in which a rare yeast was isolated from blood cultures from January 2007 to December 2016, according to recent guidelines' definitions, 4 which in summary consider rare yeast those different from Candida spp. and Cryptococcus neoformans/gattii that cause invasive infections in humans. All isolates were identified by sequencing of the ITS1-5.8S-ITS2 region. In vitro susceptibility testing was performed according to the EUCAST EDef 7.2 procedure. Given the absence of clinical breakpoints for rare yeasts, Candida albicans breakpoints were used. During this period, there were 841 episodes of yeast fungaemia in our institution including 17 isolations of rare yeasts: three of them were considered contamination of blood cultures (one Saccharomyces cerevisiae, one Rhodotorula mucilaginosa, one Magnusiomyces capitatus) and two colonizers of central venous catheters (CVCs) . As blood cultures were obtained from catheters, there were no signs of local or systemic infection and patients did not require antifungal treatment (one R. mucilaginosa, one Trichosporon asahii). Overall, 12 isolations could be considered true fungaemias (1.4% of all yeast fungaemias) caused by seven different species: R. mucilaginosa (n " 5), Trichosporon inkin (n " 2), T. asahii (n " 1), Trichosporon dermatis (n " 1), Trichosporon japonicum (n " 1), Arxula adeninivorans (n " 1) and Kodamaea ohmeri (n " 1). Incidence remained stable during the study period, with a mean of 0.02 episodes per 1000 admissions.
The main characteristics of the 12 patients are shown in Table 1 . The median age was 48 years and 66.7% of the patients were male. Overall, 8 of 12 patients (66.7%) were immunocompromised, 6 (50%) had a haematological malignancy and 6 (50%) were neutropenic. Nearly all patients (11 of 12, 91.7%) had a CVC. Most patients with trichosporonosis (4 of 5, 80%) were haematological and all of them (5 of 5, 100%) were neutropenic at the time of fungaemia.
The most common source of fungaemia was the CVC (10 of 12, 83.3%). Post-mortem necropsy detected disseminated infection in two patients with catheter-related Trichosporon fungaemia. The other presumed clinical origins were infective endocarditis and the biliary tract (one case each). Breakthrough fungaemia was observed in six patients (50%); five of them (83.3%) were receiving candins and one was receiving voriconazole (16.7%). Regarding treatment, three patients did not receive any antifungal (two died prematurely and one required catheter withdrawal only), two received an appropriate empirical antifungal and six received an appropriate targeted treatment, a mean of 6.5 days after blood culture extraction. Overall mortality was 66.7% (n " 8) and related mortality was 41.7% (n " 5).
All isolates were resistant to echinocandins. The rates of resistance to amphotericin B, fluconazole, voriconazole and posaconazole were 42%, 75%, 50% and 92%, respectively. Trichosporon isolates were mostly resistant to amphotericin B, variably susceptible to fluconazole and fully susceptible to voriconazole.
Our findings confirm that rare yeast fungaemia is still a very uncommon entity, representing only 1.4% of all our observed yeast fungaemias, which is within the 0.7%-2.8% rate 2,4,5 reported in previous series using similar definitions. Incidence remained stable over time, as reported by Bretagne et al. 1 The predominant isolation of R. mucilaginosa and Trichosporon species confirms a recent Spanish multicentre study, 6 but differs from other countries' series, 7 which could be explained by differences in local epidemiology. Trichosporon seems to be particularly common in hematologic patients as observed by Bretagne et al.,
1 who found an independent association between Trichosporon infections, haematological malignancy and previous exposure to caspofungin. We confirm these findings, with 4 of 5 (80%) of our patients with trichosporonosis having haematological malignancy, severe neutropenia and previous prophylaxis with echinocandins.
Although CVCs are the first source of infection to suspect, 2, 4, 6 infective endocarditis as well as ocular, intra-abdominal or disseminated infection have been described and should be ruled out. Disseminated trichosporonosis should be investigated in severely immunosuppressed haematologic patients with Trichosporon fungaemia, 8 as seen in two of our patients. These patients were only diagnosed after necropsy; their pre-mortem diagnosis was just catheter-related infection.
The number of patients who received inadequate or delayed antifungal therapy is a matter of concern. Physicians should keep in mind that yeast fungaemia does not always mean Candida, particularly in cases of breakthrough fungaemia affecting severely immunocompromised patients. As the current series shows, resistance to echinocandins is universal, while amphotericin B maintains activity against rare yeasts other than Trichosporon spp., in which extended-spectrum triazoles are preferable until in vitro susceptibility is available.
In conclusion, fungaemia caused by rare yeasts is still an uncommon problem in large institutions, with stable incidence but with high mortality. Therefore, rapid species identification is mandatory and empirical treatment must be carefully considered in some populations as these species possess variable antifungal susceptibility.
